JP2022542574A5 - - Google Patents
Info
- Publication number
- JP2022542574A5 JP2022542574A5 JP2022504589A JP2022504589A JP2022542574A5 JP 2022542574 A5 JP2022542574 A5 JP 2022542574A5 JP 2022504589 A JP2022504589 A JP 2022504589A JP 2022504589 A JP2022504589 A JP 2022504589A JP 2022542574 A5 JP2022542574 A5 JP 2022542574A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025131324A JP2025179060A (ja) | 2019-07-26 | 2025-08-06 | 抗ｈｅｒ２／抗４－１ｂｂ二重特異性抗体及びその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962878951P | 2019-07-26 | 2019-07-26 | |
| US62/878,951 | 2019-07-26 | ||
| US202063024608P | 2020-05-14 | 2020-05-14 | |
| US63/024,608 | 2020-05-14 | ||
| PCT/KR2020/009871 WO2021020846A1 (en) | 2019-07-26 | 2020-07-27 | Anti-her2/anti-4-1bb bispecific antibody and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025131324A Division JP2025179060A (ja) | 2019-07-26 | 2025-08-06 | 抗ｈｅｒ２／抗４－１ｂｂ二重特異性抗体及びその使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022542574A JP2022542574A (ja) | 2022-10-05 |
| JPWO2021020846A5 JPWO2021020846A5 (https=) | 2023-08-07 |
| JP2022542574A5 true JP2022542574A5 (https=) | 2023-08-07 |
| JP7725446B2 JP7725446B2 (ja) | 2025-08-19 |
Family
ID=74190718
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022504589A Active JP7725446B2 (ja) | 2019-07-26 | 2020-07-27 | 抗ｈｅｒ２／抗４－１ｂｂ二重特異性抗体及びその使用 |
| JP2025131324A Pending JP2025179060A (ja) | 2019-07-26 | 2025-08-06 | 抗ｈｅｒ２／抗４－１ｂｂ二重特異性抗体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025131324A Pending JP2025179060A (ja) | 2019-07-26 | 2025-08-06 | 抗ｈｅｒ２／抗４－１ｂｂ二重特異性抗体及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12240913B2 (https=) |
| EP (1) | EP4004054A4 (https=) |
| JP (2) | JP7725446B2 (https=) |
| KR (2) | KR102820082B1 (https=) |
| CN (2) | CN118638240A (https=) |
| AU (1) | AU2020320233A1 (https=) |
| BR (1) | BR112022001336A8 (https=) |
| CA (1) | CA3147423A1 (https=) |
| MX (1) | MX2022001022A (https=) |
| WO (1) | WO2021020846A1 (https=) |
| ZA (1) | ZA202200906B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20211147A1 (es) | 2019-08-12 | 2021-06-28 | I Mab Biopharma Us Ltd | Anticuerpos anti-claudina 18.2 y anti-4-1bb biespecificos y su uso |
| CA3169910A1 (en) * | 2020-02-28 | 2021-09-02 | Shanghai Henlius Biotech, Inc. | Anti-cd137 constructs, multispecific antibody and uses thereof |
| KR20230042524A (ko) * | 2020-08-07 | 2023-03-28 | 주식회사 유틸렉스 | 항-her2 / 항-4-1bb 이중특이적 항체 및 이의 용도 |
| EP4281467A4 (en) * | 2021-01-25 | 2024-12-04 | Yuhan Corporation | Methods for purifying an anti-4-1bb/anti-her2 bispecific antibody |
| MX2024005999A (es) * | 2021-11-19 | 2024-05-30 | Ap Biosciences Inc | Anticuerpos bispecificos dirigidos a cd137 y usos de los mismos para la inmunoterapia anticancer. |
| JP2025512915A (ja) * | 2022-04-07 | 2025-04-22 | ユハン コーポレーション | Ｈｅｒ２の発現レベルが低いがんを治療又は予防するための薬学的組成物 |
| KR20250148463A (ko) * | 2024-04-03 | 2025-10-14 | 주식회사유한양행 | 담도암의 치료를 위한 항-her2/항-4-1bb 이중 특이 항체 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100694508B1 (ko) * | 2005-05-24 | 2007-03-13 | 울산대학교 산학협력단 | Ｈｂｂｋ４항체를 포함하는 암 질환 치료용 약학조성물및 이를 이용한 암의 면역치료 방법 |
| DK2699598T3 (en) | 2011-04-19 | 2019-04-23 | Pfizer | COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER |
| EP2738180A1 (en) | 2012-11-30 | 2014-06-04 | Molecular Partners AG | Binding proteins comprising at least two binding domains against HER2. |
| CA2984624A1 (en) | 2015-03-18 | 2016-09-22 | Baylor College Of Medicine | Her2/erbb2 chimeric antigen receptor |
| KR20170138574A (ko) | 2015-05-04 | 2017-12-15 | 피어이스 파마슈티컬즈 게엠베하 | 항암 융합 폴리펩타이드 |
| CN108064246A (zh) * | 2015-06-15 | 2018-05-22 | 基因泰克公司 | 抗体和免疫结合物 |
| FI3436048T3 (fi) * | 2016-03-31 | 2025-09-15 | Biontech Us Inc | Neoantigeeneja ja niiden käyttömenetelmiä |
| AU2017252233A1 (en) * | 2016-04-22 | 2018-11-15 | Alligator Bioscience Ab | Novel bispecific polypeptides against CD137 |
| AU2017355544A1 (en) * | 2016-11-03 | 2019-05-16 | Juno Therapeutics, Inc. | Combination therapy of a T cell therapy and a BTK inhibitor |
| IL268836B2 (en) * | 2017-02-24 | 2024-04-01 | Macrogenics Inc | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof |
| SG11202000503QA (en) * | 2017-07-20 | 2020-02-27 | Aptevo Res & Development Llc | Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods |
| CN113286825B (zh) * | 2018-11-30 | 2024-06-18 | 爱必乐生物公司 | 抗pd-l1/抗4-1bb双特异性抗体及其用途 |
-
2020
- 2020-07-27 US US16/939,536 patent/US12240913B2/en active Active
- 2020-07-27 BR BR112022001336A patent/BR112022001336A8/pt unknown
- 2020-07-27 AU AU2020320233A patent/AU2020320233A1/en active Pending
- 2020-07-27 CA CA3147423A patent/CA3147423A1/en active Pending
- 2020-07-27 KR KR1020227006642A patent/KR102820082B1/ko active Active
- 2020-07-27 CN CN202410786028.6A patent/CN118638240A/zh active Pending
- 2020-07-27 KR KR1020257019038A patent/KR20250090381A/ko active Pending
- 2020-07-27 MX MX2022001022A patent/MX2022001022A/es unknown
- 2020-07-27 CN CN202080054005.6A patent/CN114206941B/zh active Active
- 2020-07-27 EP EP20848659.7A patent/EP4004054A4/en active Pending
- 2020-07-27 WO PCT/KR2020/009871 patent/WO2021020846A1/en not_active Ceased
- 2020-07-27 JP JP2022504589A patent/JP7725446B2/ja active Active
-
2022
- 2022-01-19 ZA ZA2022/00906A patent/ZA202200906B/en unknown
-
2025
- 2025-01-23 US US19/034,755 patent/US20250163180A1/en active Pending
- 2025-08-06 JP JP2025131324A patent/JP2025179060A/ja active Pending